MorphoSys (MOR)

MorphoSys AG

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MOR

<< Previous 1 2 3

Date	Time	Source	Headline	Symbol	Company
02/06/2021	12:40	GlobeNewswire Inc.	Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys	NASDAQ:MOR	MorphoSys AG
02/06/2021	12:25	Business Wire	MorphoSys to Acquire Constellation Pharmaceuticals	NASDAQ:MOR	MorphoSys AG
12/05/2021	16:26	Business Wire	Incyte und MorphoSys melden Dosierung des ersten Patienten in Phase-3-Studie frontMIND zur Prüfung von Tafasitamab-Kombinati...	NASDAQ:MOR	MorphoSys AG
11/05/2021	21:01	Business Wire	Incyte & MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line...	NASDAQ:MOR	MorphoSys AG
19/04/2021	21:01	Business Wire	Incyte & MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomid...	NASDAQ:MOR	MorphoSys AG
12/01/2021	21:00	PR Newswire (Canada)	Incyte et MorphoSys annoncent que Santé Canada accepte leur présentation de drogue nouvelle pour le tafasitamab	NASDAQ:MOR	MorphoSys AG
12/01/2021	21:00	PR Newswire (Canada)	Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab	NASDAQ:MOR	MorphoSys AG
07/12/2020	15:00	Business Wire	Data Evaluating Tafasitamab with & without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020	NASDAQ:MOR	MorphoSys AG
17/09/2020	21:03	Business Wire	Incyte & MorphoSys to Host Investor Event to Discuss the Unmet Need & Global Opportunities for Tafasitamab in Non-Hodgkin Lym...	NASDAQ:MOR	MorphoSys AG
18/08/2020	21:02	Business Wire	National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for...	NASDAQ:MOR	MorphoSys AG
01/08/2020	00:51	Business Wire	FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed ...	NASDAQ:MOR	MorphoSys AG
27/04/2020	21:01	GlobeNewswire Inc.	I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainlan...	NASDAQ:MOR	MorphoSys AG
27/09/2018	11:17	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	NASDAQ:MOR	MorphoSys AG
27/09/2018	11:11	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	NASDAQ:MOR	MorphoSys AG
21/09/2018	15:04	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	NASDAQ:MOR	MorphoSys AG
21/09/2018	15:03	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	NASDAQ:MOR	MorphoSys AG
18/09/2018	14:48	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	NASDAQ:MOR	MorphoSys AG
18/09/2018	08:52	Business Wire	LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics	NASDAQ:MOR	MorphoSys AG
06/09/2018	12:33	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	NASDAQ:MOR	MorphoSys AG
08/08/2018	02:01	PR Newswire (US)	I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202	NASDAQ:MOR	MorphoSys AG
19/07/2018	13:51	Dow Jones News	Novartis, MorphoSys and Galapagos Shares Rise on News of Deal	NASDAQ:MOR	MorphoSys AG
19/04/2018	21:24	GlobeNewswire Inc.	Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market	NASDAQ:MOR	MorphoSys AG
07/12/2014	03:01	DPA AFX Nachrichten	GNW-News: MorphoSys und Xencor veröffentlichen finale Ergebnisse der Phase 1/2a-Studie von MOR208 in CLL/SLL auf der ASH-Jahre	LSE:MOR	MORPHOSYS
10/08/2013	07:56	DPA AFX Nachrichten	TR ONE Ad Hoc: Ad hoc: Erfolgreicher Vollzug der MOR202-Allianz, MorphoSys erhöht Finanzprognose und gibt 3,4 %-iges Aktienpak	LSE:MOR	MORPHOSYS